Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Portfolio Pulse from
Inventiva will present final data from a Phase 2 study on lanifibranor combined with empagliflozin for MASH and T2D at the AASLD Liver Meeting.
November 15, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva is set to present final data from its Phase 2 study on lanifibranor combined with empagliflozin for MASH and T2D at the AASLD Liver Meeting. This could impact investor sentiment positively if the results are favorable.
The presentation of final Phase 2 data at a major conference like AASLD can significantly influence investor sentiment. If the data is positive, it could lead to increased investor confidence and a potential rise in stock price. The focus on MASH and T2D, areas with unmet medical needs, adds to the potential impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90